A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock fell sharply Tuesday following disappointing results from a key clinical ...

Despite disruptions and restructuring costs, Sarepta Therapeutics Inc (SRPT) showcases strong revenue performance and ...

Monday after the biotechnology company disclosed disappointing drug-trial data, which could lengthen the timeline of the ...

Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid ...

Sarepta Therapeutics' shares plunged nearly 40% in premarket trading on Tuesday as failure of two of its approved drugs for a ...

Sarepta Therapeutics shares plunged 37% after two Duchenne muscular dystrophy drugs failed a key trial, raising regulatory ...

Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting ...

Shares plunge 36% after nine-year DMD drug trial misses endpoint. Q3 revenue beats but clinical failure dominates sentiment.

Shares in Sarepta Therapeutics lost nearly 40% of their value after the company said a trial designed to confirm the efficacy ...

Sarepta Therapeutics' shares plunged nearly 30% on Tuesday as the failure of two of its approved drugs in a key trial and ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2025 and the completion of ESSENCE, its ...